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In June 2013, a subclinical infection with severe fe-
ver with thrombocytopenia syndrome virus (SFTSV) was 
detected in Zhejiang Province, China, prompting serop-
revalence studies in 6 districts within the province. Of 986 
healthy persons tested, 71 had IgG antibodies against 
SFTSV. This finding suggests that most natural infections 
with SFTSV are mild or subclinical.
Severe fever with thrombocytopenia syndrome (SFTS), a serious emerging infectious disease, was first re-
ported in rural areas of central China in 2009 (1). The 
characteristic signs and symptoms of SFTS include fever, 
thrombocytopenia, and leukocytopenia, and the disease 
has a case-fatality rate of up to 30%. SFTS is caused by 
infection with SFTS virus (SFTSV; family Bunyaviridae, 
genus Phlebovirus). The virus was first isolated in 2010 
from patients with SFTS (1); since then, additional cases 
have been reported from many areas of China (2,3). Af-
ter the occurrence of SFTS cases in Zhejiang Province, 
China, in 2013, enhanced surveillance for the disease was 
implemented (4). We report on the first human case of 
SFTS in a rural area of Pujiang district in Zhejiang Prov-
ince and on an apparently associated mild or subclinical 
case of SFTSV infection in a family member of the pa-
tient. In addition, to determine if other mild or subclini-
cal infections had occurred, we conducted seropreva-
lence studies in the patient’s village and 5 other Zhejiang 
Province districts. The study was approved by the Ethics 
Committee of the Zhejiang Provincial Center for Disease 
Control and Prevention.
The Study
A human case of SFTS was identified in a rural area 
of the Pujiang district (Figure 1). The patient, a 60-year-
old local male subsistence farmer, sought treatment at the 
Zhejiang Provincial People’s Hospital on June 1, 2012, 
after a 6-day history of fever (maximum axillary tempera-
ture 40°C), malaise, chills, gingival bleeding, hyperemia of 
conjunctivae, and diarrhea (10 or fewer times per day). Ini-
tial laboratory testing revealed thrombocytopenia (13 × 109 
platelets/L; reference range 100–300 × 109 platelets/L) and 
leukocytopenia (0.93 × 109 leukocytes/L; reference range 
4–10 × 109/L). Supportive therapy was provided, and the 
patient’s condition seemed to improve on the second day: 
platelet count rose to 34 × 109 platelets/L, and leukocyte 
count rose to 7.28 × 109 leukocytes/L. However, on the 
third day, the patient became weak and died of multiple 
organ failure.
Serum samples from the patient were tested for the 
presence of SFTSV RNA by quantitative real-time reverse 
transcription PCR as previously described (1). The QIAamp 
Viral RNA Mini Kit (QIAGEN, Hilden, Germany) was used 
for RNA extraction. Detection of all 3 viral RNA segments 
by quantitative real-time reverse transcription PCR and iso-
lation of the virus from Vero cell culture confirmed the as-
sociation between the clinical syndrome and SFTSV infec-
tion. In addition, SFTSV-specific IgG and low levels of viral 
RNA were detected in a blood sample from a family member 
of the patient. The family member did not report exposure to 
potential animal hosts or vectors, so SFTSV transmission is 
believed to have occurred through personal contact when the 
family member was caring for the patient. Signs of illness 
did not develop in the family member.
To investigate if additional mild subclinical infections 
occurred, we, with the support of the local disease control 
department, conducted a seroprevalence study in the pa-
tient’s village in Pujiang district. A total of 54 blood sam-
ples were collected from 54 healthy volunteers. We used 
an ELISA kit provided by the National Center for Disease 
Control and Prevention to prepare and test serum samples 
for the presence of SFTSV-specific IgM and IgG (5,6). This 
ELISA compares well with serum neutralization assays for 
SFTSV (6). All serum samples were negative for SFTSV-
specific IgM, whereas 4 (7.4%) of the serum samples were 
positive for SFTSV-specific IgG (Figure 2). None of the 
IgG-positive participants reported any disease symptoms 
that are associated with SFTSV infections.
To further investigate the occurrence of mild or sub-
clinical SFTSV infections, we collected serum samples 
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from healthy volunteers in 5 additional districts in Zheji-
ang Province and tested the samples for SFTSV-specific 
IgG. The percentages of positive samples, by district, 
follow (the no. positive/total no. tested are shown in pa-
rentheses): Lishui, 10.2% (18/176); Jinhua, 3.5% (7/200); 
Ningbo, 10.9 (28/256); Taizhou, 3% (3/100); and Jiaxing, 
5.5% (11/200) (Figure 2). Results were confirmed by im-
munofluorescence assay conducted as previously reported 
(1). In brief, SFTSV-infected Vero cells were fixed with 
cold acetone, washed with distilled water, air-dried, and 
then stored at –70°C. Serum samples were diluted 1:20 
in phosphate-buffered saline supplemented with 0.01% 
Evans blue (Sigma-Aldrich Co. LLC, St. Louis, MO, 
USA). Slides were then incubated with the diluted serum 
samples in a humidified chamber at 37°C for 30 min and 
then washed with phosphate-buffered saline. The wells 
were incubated with fluorescein isothiocyanate–labeled 
goat anti–human IgG conjugate (Boshide, Wuhan, Chi-
na), washed, and analyzed by the use of fluorescence mi-
croscopy. The results of these experiments confirmed the 
presence of SFTSV-specific IgG in 84.5% (60/71) of the 
samples with ELISA-positive results. Serum samples that 
were negative for SFTSV by ELISA were also negative 
by immunofluorescence assay.
Conclusions
SFTSV can cause severe disease and high rates of 
death among infected hospitalized patients. The virus also 
has the limited ability to be transmited from person to per-
son through contact with contaminated blood, but second-
ary cases are generally less severe and have so far not re-
sulted in fatalities (7–9). Nonetheless, there is great public 
health concern regarding SFTSV.
Our seroprevalence study was prompted by the identi-
fication of a subclinical, secondary infection that was most 
likely caused by person-to-person transmission of the vi-
rus from an infected family member with a fatal case of 
SFTS. We found an overall SFTSV seroprevalence of 7.2% 
among 986 healthy persons who reported no symptoms as-
sociated with SFTS. Because the seropositive participants 
in our study did not have contact with persons with diag-
nosed cases of SFTS, their infections most likely occurred 
through natural exposure. From this, we conclude that 
SFTSV infections are widespread in rural areas of Zheji-
ang Province, and only a small percentage of the infections 
result in clinical disease.
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Figure 1. Location of Zhejiang 
Province in China (left) and the 
location of selected districts (right) 
within the province where serum 
samples of healthy persons were 
collected and tested in 2013 for 
the presence of severe fever with 
thrombocytopenia syndrome virus–
specific IgG and IgM.
Figure 2. Seroprevalence of IgG to severe fever with 
thrombocytopenia syndrome virus in healthy persons from selected 
districts in Zhejiang Province, China, 2013.
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